Your browser doesn't support javascript.
loading
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma.
Kaiser, Martin F; Hall, Andrew; Walker, Katrina; Sherborne, Amy; De Tute, Ruth M; Newnham, Nicola; Roberts, Sadie; Ingleson, Emma; Bowles, Kristian; Garg, Mamta; Lokare, Anand; Messiou, Christina; Houlston, Richard S; Jackson, Graham; Cook, Gordon; Pratt, Guy; Owen, Roger G; Drayson, Mark T; Brown, Sarah R; Jenner, Matthew W.
Afiliação
  • Kaiser MF; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.
  • Hall A; Department of Haematology, The Royal Marsden Hospital, London, United Kingdom.
  • Walker K; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
  • Sherborne A; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
  • De Tute RM; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.
  • Newnham N; Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, United Kingdom.
  • Roberts S; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
  • Ingleson E; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
  • Bowles K; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
  • Garg M; Department of Haematology, Norfolk and Norwich University Hospitals NHS Trust, Norwich, United Kingdom.
  • Lokare A; Department of Haematology, Leicester Royal Infirmary, Leicester, United Kingdom.
  • Messiou C; Department of Haematology, Birmingham Heartlands, Birmingham, United Kingdom.
  • Houlston RS; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.
  • Jackson G; Department of Haematology, The Royal Marsden Hospital, London, United Kingdom.
  • Cook G; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.
  • Pratt G; Department of Haematology, Newcastle University, Newcastle, United Kingdom.
  • Owen RG; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
  • Drayson MT; Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, United Kingdom.
  • Brown SR; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
  • Jenner MW; Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, United Kingdom.
J Clin Oncol ; 41(23): 3945-3955, 2023 08 10.
Article em En | MEDLINE | ID: mdl-37315268
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Mieloma Múltiplo Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Mieloma Múltiplo Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article